Theravance Biopharma (TBPH) Given Daily Coverage Optimism Score of 0.10
Media headlines about Theravance Biopharma (NASDAQ:TBPH) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Theravance Biopharma earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 46.1110058274164 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Several research analysts recently weighed in on the stock. BidaskClub raised shares of Theravance Biopharma from a “sell” rating to a “hold” rating in a report on Friday, July 6th. ValuEngine downgraded shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Saturday, August 18th. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $55.00 target price on shares of Theravance Biopharma in a report on Wednesday, August 1st. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $40.00 target price on shares of Theravance Biopharma in a report on Wednesday, August 1st. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company’s stock. Theravance Biopharma currently has an average rating of “Hold” and a consensus price target of $40.00.
Theravance Biopharma stock traded up $0.55 during mid-day trading on Friday, hitting $29.28. The stock had a trading volume of 1,504 shares, compared to its average volume of 142,976. The company has a market capitalization of $1.60 billion, a P/E ratio of -5.34 and a beta of 1.90. The company has a debt-to-equity ratio of 6.52, a quick ratio of 3.95 and a current ratio of 4.14. Theravance Biopharma has a one year low of $21.27 and a one year high of $35.90.
In other Theravance Biopharma news, CFO Renee D. Gala sold 43,743 shares of the stock in a transaction dated Wednesday, August 15th. The shares were sold at an average price of $26.79, for a total transaction of $1,171,874.97. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Bradford J. Shafer sold 7,119 shares of the stock in a transaction dated Monday, August 27th. The shares were sold at an average price of $27.71, for a total transaction of $197,267.49. Following the transaction, the executive vice president now directly owns 84,000 shares of the company’s stock, valued at approximately $2,327,640. The disclosure for this sale can be found here. Insiders sold a total of 82,162 shares of company stock valued at $2,243,664 in the last ninety days. 6.10% of the stock is currently owned by insiders.
About Theravance Biopharma
Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria.
Featured Article: Hedge Funds Explained
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.